Detalhe da pesquisa
1.
CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
Clin Infect Dis
; 72(10): 1730-1737, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198515
2.
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Clin Infect Dis
; 73(6): 1003-1012, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822015
3.
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
N Engl J Med
; 373(13): 1195-206, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26214039
4.
Controlled human infection trials: Legitimacy and conditions of implementation in France.
Therapie
; 79(1): 35-45, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105120
5.
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
EClinicalMedicine
; 62: 102109, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37533419
6.
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
Lancet Microbe
; 3(6): e427-e434, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35659904
7.
Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.
Microbiol Spectr
; 10(3): e0071121, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35604130
8.
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.
J Infect Dis
; 201(3): 370-7, 2010 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20059357
9.
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
Lancet Infect Dis
; 21(4): 529-536, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33212068
10.
Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Vaccine
; 38(41): 6472-6477, 2020 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32773243
11.
Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Vaccine
; 38(19): 3531-3536, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32204943
12.
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Pediatr Infect Dis J
; 23(2): 99-109, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14872173
13.
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Am J Trop Med Hyg
; 66(3): 264-72, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12139219
14.
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Hum Vaccin Immunother
; 10(10): 2853-63, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25483647
15.
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
Pediatr Infect Dis J
; 30(1): e9-17, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21042231
16.
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
Am J Trop Med Hyg
; 85(4): 724-31, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21976579
17.
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
Vaccine
; 29(22): 3863-72, 2011 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-21477675
18.
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Vaccine
; 26(45): 5712-21, 2008 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-18762226
19.
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Vaccine
; 24(9): 1238-41, 2006 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-16213632
20.
Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).
Vaccine
; 24(23): 4914-26, 2006 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-16632108